Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 346

Sort by

Sort Order Select

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Tomas Jose Gonzalez-Lopez, Nuria Bermejo, Rocío Cardesa-Cabrera, Violeta Martínez, Gerardo Aguilar-Monserrate, Gloria Pérez Segura, Abel Domingo García, Josefa Luis-Navarro, Sunil Lakhwani, Natalia Acedo, Maria L Lozano, Silvia Bernat, Ana Torres-Tienza, Ana Ruano, Isidro Jarque, Pilar Galán Alvarez, Carmen Benet Campos, Shally Marcellini-Antonio, Reyes Jimenez-Bárcenas, Daniel Martínez-Carballeira, Dunia de Miguel Llorente, Álvaro Perona Blázquez, Isabel González-Gascón-y-Marín, Elsa Lopez-Ansoar, José María Alonso Alonso, María Luisa Bengochea-Casado, FJ Díaz Gálvez, Ana Moretó, Gemma Moreno, Roberto Hernández-Martin, Erik de Cabo, Julio Davila-Valls, Amalia Cuesta, Carmen Pastoriza Cruz, Gerardo Hermida, Covadonga García, Miguel Angel Pozas-Mañas, Carlos Aguilar-Franco, Dolores Fernandez-Jimenez, Begoña Navas-Elorza, Carolina López-Santamaría Castro, Alvaro Lorenzo Vizcaya, Xavier Ortín, Marta garcia pintos, Sonia Piernas, Johana Díaz-Santa, Inmaculada Soto-Ortega, Dr, Drew Provan, Gloria García-Donas Gabaldón

Blood blood.2024024250.

https://doi.org/10.1182/blood.2024024250

Published: 2024

Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus

Blood (2024) 143 (20): 2099–2105.

https://doi.org/10.1182/blood.2024024166

Published: 2024

Includes: Supplemental data

Journal Articles

Pilot Study of Longitudinal Geriatric Assessment and Neurocognitive Evaluation in CAR T-Cell Therapy for Older Patients with Relapsed Refractory, Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 7406.

https://doi.org/10.1182/blood-2023-190497

Published: 2023

Journal Articles

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Toshihisa Satta, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Pamela Susman, Amandeep Singh, Marco Calafiore, Sergio A. Giralt, Miguel-Angel Perales, Jianmin Chen, Simon Li, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2023-181269

Published: 2023

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 429.

https://doi.org/10.1182/blood-2023-179972

Published: 2023

Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Blood (2023) 142 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2023-189196

Published: 2023

Journal Articles

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Beatriz Wills, Roni Shouval, Jessica R. Flynn, Sean M. Devlin, Allison Parascondola, Amethyst Saldia, Brandon S. Imber, Ana Alarcon Tomas, Ivan Landego, Richard J. Lin, Michael Scordo, Parastoo Bahrami Dahi, Gunjan L. Shah, Andrew Ip, Lori A Leslie, Hyung Chan Suh, Gilles Salles, Miguel-Angel Perales, Maria Lia Palomba

Blood (2023) 142 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2023-181116

Published: 2023

Journal Articles

Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

Blood (2023) 142 (Supplement 1): 2591.

https://doi.org/10.1182/blood-2023-190511

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy

Blood (2023) 142 (Supplement 1): 4970.

https://doi.org/10.1182/blood-2023-182733

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2023-189349

Published: 2023

Journal Articles

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Sanam Shahid, Georgia C Flynn, Audrey Mauguen, Jennifer Bieler, Susan E Prockop, Andromachi Scaradavou, Jaap Jan Boelens, Craig S Sauter, Miguel-Angel Perales, Sergio A. Giralt, Xiuyan Wang, Isabelle Riviere, Michel Sadelain, Renier Brentjens, Nancy A Kernan, Richard J O'Reilly, Kevin J Curran

Blood (2023) 142 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2023-180753

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

NARROW

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Pilot Study of Longitudinal Geriatric Assessment and Neurocognitive Evaluation in CAR T-Cell Therapy for Older Patients with Relapsed Refractory, Large B-Cell Lymphoma

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only